Homegrown pharma major Lupin on Wednesday said it has received GMP Certificate from Pharmaceutical and Medical Devices Agency, Japan for its Mandideep active pharmaceutical ingredients (API) facility. The GMP (good manufacturing practice) Certificate was issued following an inspection conducted by PMDA between May 14, 2019 and May 17, 2019, Lupin said in a regulatory filing. Pharmaceutical and Medical Devices Agency (PMDA) inspection closed with no critical or major observations. The GMP Certificate issued by the Japanese agency for Mandideep facility (Unit II) is valid till September 2024, it added. Lupin develops and sells a wide range of branded and generic formulations, biotechnology products and APis globally.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!